Möchten Sie immer auf dem neuesten Stand bleiben?

VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies  KT-621...

PS-1001 is a potent, long-acting inflammasome inhibitor. New data support its therapeutic promise for a wide range of chronic inflammatory diseases.

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...

Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass.,...

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models  KT-579 Phase 1 healthy volunteer...

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.